March 3, 2017

March 03, 2017

Runners take to the street to fight cancer
WINK – March 3
Candice Pemberton, president of the Fort Myers track club, says it’s all so they can “raise money for the Golisano Children’s Hospital, Barbara’s Friends, and the Moffitt Cancer Research Center.”

Old Red Dye shows promise as new cancer foe
Asian World – March 3
“This is one of the really neat examples of what we call repurposing, taking drugs that been around for years … and suddenly realizing that they may have an oncologic value,” said Dr Vernon Sondak, head of cutaneous oncology at the Moffitt Cancer Center in Tampa, Florida. Sondak has been running clinical trials for Provectus.

Risk & reward: Stopping a cancer drug to see if you’re cured
Associated Press – March 2
Half a dozen smaller studies have been done, and “the data are all the same and it all looks good,” said Dr. Kendra Sweet of the Moffitt Cancer Center in Tampa. She helped draft new National Comprehensive Cancer Network guidelines that say it’s reasonable to consider stopping treatment in people who have been in deep remission for at least two years, with close monitoring.
Also seen in the Jamaican Observer, All on Georgia, WRAL, Salon, Miami Herald, San Francisco Gate and the Boston Globe.

Regional Chemotherapy Technique May Help Prevent Amputations
Oncology Nurse Advisor – March 2
The researchers used regional chemotherapy with isolated limb perfusion (ILI) in 77 patients with treatment-resistant, locally advanced soft tissue sarcomas. They were able to salvage limbs in 77.9% of the cases. The study, which was conducted at the Moffitt Cancer Center in Tampa, Florida, suggested that isolated limb infusion is a safe and effective technique for patients with locally advanced soft tissue sarcoma.

CAR T-Cell Therapy turns blood cells into cancer fighters
KABC – March 1
"It's pretty amazing to see patients go into remission, that we really had low hope of standard therapies working," said Dr. Frederick Locke, an oncologist at Moffitt Cancer Center.

Gene therapy extraordinary at fighting blood cancer
New Zealand Herald – March 2, 2017
"The numbers are fantastic," said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study.
"These are heavily treated patients who have no other options."

Colorectal Cancers Are Increasing in Millennials—7 Symptoms to Know
SELF Magazine – March 1
There are other environmental and lifestyle factors associated with an increased risk for colorectal cancers, Mark Friedman, M.D., a gastroenterologist at Moffitt Cancer Center, tells SELF. “These are things like lack of exercise, unhealthy eating, and diabetes—all of which are prevalent in millennials,” he says.

Terminal Cancer Patients Go Into Complete Remission After Groundbreaking Gene Therapy
Huffington Post – Mar. 1
Speaking to AP Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa said “The numbers are fantastic, these are heavily treated patients who have no other options.”

More than half of terminal cancer patients enter remission after being given a groundbreaking new gene therapy
Daily Mail – Feb. 28
'The numbers are fantastic,' said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study. 

Gene therapy to fight a blood cancer succeeds in major study
Associated Press – Feb. 28
"The numbers are fantastic," said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite. "These are heavily treated patients who have no other options."
Also seen in: CBS News, Boston Globe, Huffington Post, Edmonton Journal, Newsday, Colorado Springs Gazette, KWWL, WPVI, Fort Wayne Journal Gazette, StatNews, Detroit News, WIL Radio, Reading Eagle, Newser, BlueRidgeNow, Indiana Gazette, Houston Chronicle, San Francisco Gate, Latest Nigerian News, Fostoria Review Times, Portland Press Herald, UK Mirror, Orange County Register, Greensburg Indiana Daily News, WPVI and Idaho Statesman.

Terminal cancer patients in complete remission after one gene therapy treatment
The Telegraph – Feb. 28
"The numbers are fantastic," said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study. "These are heavily treated patients who have no other options."

Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma
Healio.com – Feb. 28
“We know as clinicians that patients with aggressive lymphoma who do not respond to their previous treatments have a very poor prognosis. In fact, we know from the SCHOLAR-1 study, these patients have only an 8% chance of achieving a complete response with current therapies,” co-lead investigator Frederick L. Locke, MD, director of research for the immune cell therapy program at Moffitt Cancer Center, said in a press release.

Education, Coordination Crucial to Successful CAR T Therapy
Cure – Feb. 28
“In treating these patients, nursing was originally not involved,” said Beaupierre, transplant nurse coordinator at the Moffitt Cancer Center.

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
Yahoo Finance – Feb. 28
“We know as clinicians that patients with aggressive lymphoma who do not respond to their previous treatments have a very poor prognosis. In fact, we know from the SCHOLAR-1 study, these patients have only an eight percent chance of achieving a complete response with current therapies,” said Frederick L. Locke, M.D., ZUMA-1 Co-Lead Investigator, and Director of Research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. 
Also seen on StreetInsider.com

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer
Pipeline Review – Feb. 28
Pre-clinical studies conducted at Sweden’s Karolinska Institute have demonstrated that Vycellix’s molecules significantly enhance cancer targeting cytotoxic lymphocytes such as cytotoxic T cells and natural killer cells (NK cells). The Moffitt team, led by James J Mulé, Ph.D., Associate Center Director for Translational Science, will conduct additional studies evaluating each molecule’s respective ability to improve genetic modification of cancer immune lymphocytes and increase their killing capacity.
Also seen on FirstWord Pharma, Pharmiweb, WBOY and BioFlorida.

Dr Miriam Stoppard: Restoring breast sensation after surgery is the holy grail
The Mirror – Feb. 27
Dr Christine Laronga, a breast oncologist at the Moffitt Cancer Center in Tampa, Florida, said she tries to be honest with patients that feeling won’t be restored after reconstruction, telling them, “It may look like a breast, but it won’t feel like a breast.”

Alix Beaupierre on Patient Education for CAR T-cell Therapy Clinical Trials
Oncology Nursing News – Feb. 27
Alix Beaupierre, RN, BSN, OCN, Moffitt Cancer Center, discusses the patient education necessary for CAR T-cell therapy clinical trials.

CAR T-Cell Therapy: Nursing's Key Role in Educating Patients, Caregivers About What to Expect
Oncology Nursing News – Feb. 27
“In treating these patients, nursing was originally not involved,” said Beaupierre, transplant nurse coordinator at the Moffitt Cancer Center. “There was a lot of patient and loved one distress. The patients didn’t have anything concrete to visualize telling them what they’re going to experience.

Treatment Has High Response Rates in Aggressive Lymphoma
Cure Today – Feb. 27
The study demonstrated that adverse event management could be effectively implemented across 22 sites, “most with no prior CAR T cell therapy experience,” said Locke, translational researcher, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center.

Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma
OncLive – Feb. 27
The durable CR rate at 3 months was 39%, which was 6-fold higher than that in historical controls, announced lead investigator Frederick L. Locke, MD. Axicabtagene ciloleuce was successfully manufactured in 99% of cases, with an average 17-day turnaround from apheresis to clinical site. There were 22 sites involved in the study.

Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy
OncLive – Feb. 26
“In treating these patients, nursing was originally not involved,” said Beaupierre, transplant nurse coordinator at the Moffitt Cancer Center. “There was a lot of patient and loved one distress. The patients didn’t have anything concrete to visualize telling them what they’re going to experience.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma
OncLive – Feb. 25
Frederick Locke, MD, Moffitt Cancer Center, discusses the interim results of the phase II pivotal ZUMA-1 trial of the anti-CD19 CAR T-cell therapy KTE-C19 for patients with refractory aggressive non-Hodgkin's lymphoma.

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML
OncLive – Feb. 24
Jeffrey Lancet, MD, of Moffitt Cancer Center, explains the use of CPX-351 compared with induction chemotherapy for older adult patients with acute myeloid leukemia (AML).

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.